Get the Stockscreener App
21.38
0.52%
0.11
After Hours:
21.44
0.06
+0.28%
Pacira Biosciences Inc stock is traded at $21.38, with a volume of 831.24K.
It is up +0.52% in the last 24 hours and down -17.04% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$21.27
Open:
$21.27
24h Volume:
831.24K
Relative Volume:
1.30
Market Cap:
$960.66M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
14.74
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-1.66%
1M Performance:
-17.04%
6M Performance:
-20.52%
1Y Performance:
+28.80%
1-Day Range:
$20.96
$21.77
1-Week Range:
$20.50
$21.85
52-Week Range:
$16.00
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.38 | 955.72M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Chart based analysis of Pacira BioSciences Inc. trendsJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Why Pacira BioSciences Inc. (82P) stock could outperform next yearJuly 2025 Volume & Community Consensus Picks - newser.com
Pacira BioSciences Inc. recovery potential after sell off2025 Market Overview & Community Consensus Stock Picks - newser.com
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Building trade automation scripts for Pacira BioSciences Inc.2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Real time social sentiment graph for Pacira BioSciences Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Is Pacira BioSciences Inc. stock poised for growthBuy Signal & Free Accurate Trade Setup Notifications - newser.com
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com
Pacira BioSciences Inc. stock retracement – recovery analysis2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Pacira Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Trends - Markets Mojo
Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Pacira BioSciences (Nasdaq: PCRX) sets Nov. 6 third-quarter results; call at 4:30 p.m. ET - Stock Titan
Will Pacira BioSciences Inc. stock keep outperforming rivalsMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Market Trend Review & Weekly Momentum Stock Picks - newser.com
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-To-Severe Osteoarthritis of the Knee - MarketScreener
Pacira BioSciences (PCRX) Reports Promising Three-Year Findings for PCRX-201 - GuruFocus
Is Pacira BioSciences Inc. stock a buy on dipsForecast Cut & Smart Investment Allocation Insights - Fundação Cultural do Pará
Pacira Biosciences Increceives Paragraph IV notice from Qilu Pharmaceutical - MarketScreener
Pacira BioSciences receives patent challenge for EXPAREL from Chinese firm - Investing.com
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - The Manila Times
Pacira BioSciences Receives PIV Notice from Qilu Pharmaceutical Regarding Generic EXPAREL Patent Claims - Quiver Quantitative
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):